|
|
Article: GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years.
- Article from:
- PR Newswire
- Article date:
- March 10, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New study results also demonstrate the longest duration of consistently high antibody levels shown by a cervical cancer vaccine
TAMPA, Fla., March 10 /PRNewswire-FirstCall/ -- New data demonstrate that GlaxoSmithKline's cervical cancer candidate vaccine, CERVARIX(R) provides significant protection for women against the four most common cancer- causing human papillomavirus types for nearly six and a half years, the longest duration of protection reported to date. Over this time, the cervical cancer candidate vaccine showed 100 percent efficacy in preventing precancerous lesions due to cancer-causing virus types 16 and 18 and also provided substantial protection ...